FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804373208> ?p ?o ?g. }

• W2804373208 endingPage "1207" @default.
• W2804373208 startingPage "1199" @default.
• W2804373208 abstract "•Presenting the design and rationale of the HAUSER-RCT study.•HAUSER-RCT is a randomized ongoing study of evolocumab in children aged 10–17 years.•All participants have familial hypercholesterolemia on statin, with low-density lipoprotein cholesterol ≥130 mg/dL.•Randomization is 2:1 to blinded evolocumab or placebo for 24 weeks. BackgroundEvolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is safe and effective in reducing low-density lipoprotein cholesterol in adults with familial hypercholesterolemia. A dedicated study, HAUSER-RCT, is being conducted to examine the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH).ObjectiveTo present the rationale and design of the HAUSER-RCT study.MethodsThe HAUSER-RCT study is a double-blind, randomized, multicenter, placebo-controlled study designed to characterize the efficacy, safety, and tolerability of evolocumab treatment as an add-on to diet and lipid-lowering therapy, including a stable, optimized dose of statin, in pediatric patients aged 10 to 17 years with HeFH. Approximately, 150 patients will be randomized in a 2:1 ratio to receive 24 weeks of monthly evolocumab or placebo. The study will include approximately 51 sites located in North America, South America, Europe, South Africa, Australia, and New Zealand. The primary efficacy endpoint is the percent change in low-density lipoprotein cholesterol from baseline to week 24. A key secondary efficacy endpoint is the percent change in other lipid parameters from baseline to week 24. Other assessments include Tanner staging, carotid intima-media thickness, and cognitive tests. At the end of the study, consenting patients can participate in an 18-month open-label extension study (HAUSER-OLE).ResultsThe study is ongoing and the results will be communicated at the end of the study.ConclusionsThe HAUSER-RCT study, the largest randomized, placebo-controlled study with proprotein convertase subtilisin/kexin type 9 inhibitors being conducted in the pediatric HeFH population, aims to provide efficacy, safety, and tolerability data of evolocumab as an add-on therapy in these patients. Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is safe and effective in reducing low-density lipoprotein cholesterol in adults with familial hypercholesterolemia. A dedicated study, HAUSER-RCT, is being conducted to examine the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). To present the rationale and design of the HAUSER-RCT study. The HAUSER-RCT study is a double-blind, randomized, multicenter, placebo-controlled study designed to characterize the efficacy, safety, and tolerability of evolocumab treatment as an add-on to diet and lipid-lowering therapy, including a stable, optimized dose of statin, in pediatric patients aged 10 to 17 years with HeFH. Approximately, 150 patients will be randomized in a 2:1 ratio to receive 24 weeks of monthly evolocumab or placebo. The study will include approximately 51 sites located in North America, South America, Europe, South Africa, Australia, and New Zealand. The primary efficacy endpoint is the percent change in low-density lipoprotein cholesterol from baseline to week 24. A key secondary efficacy endpoint is the percent change in other lipid parameters from baseline to week 24. Other assessments include Tanner staging, carotid intima-media thickness, and cognitive tests. At the end of the study, consenting patients can participate in an 18-month open-label extension study (HAUSER-OLE). The study is ongoing and the results will be communicated at the end of the study. The HAUSER-RCT study, the largest randomized, placebo-controlled study with proprotein convertase subtilisin/kexin type 9 inhibitors being conducted in the pediatric HeFH population, aims to provide efficacy, safety, and tolerability data of evolocumab as an add-on therapy in these patients." @default.
• W2804373208 created "2018-06-01" @default.
• W2804373208 creator A5003714120 @default.
• W2804373208 creator A5009467334 @default.
• W2804373208 creator A5016352406 @default.
• W2804373208 creator A5020436935 @default.
• W2804373208 creator A5025538949 @default.
• W2804373208 creator A5028132133 @default.
• W2804373208 creator A5035587883 @default.
• W2804373208 creator A5044425699 @default.
• W2804373208 creator A5069071892 @default.
• W2804373208 creator A5090781778 @default.
• W2804373208 date "2018-09-01" @default.
• W2804373208 modified "2023-10-12" @default.
• W2804373208 title "Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study" @default.
• W2804373208 cites W1113293211 @default.
• W2804373208 cites W1599578988 @default.
• W2804373208 cites W1807141364 @default.
• W2804373208 cites W1970484759 @default.
• W2804373208 cites W1978080134 @default.
• W2804373208 cites W1981212842 @default.
• W2804373208 cites W2014263073 @default.
• W2804373208 cites W2016063327 @default.
• W2804373208 cites W2016805353 @default.
• W2804373208 cites W2023735564 @default.
• W2804373208 cites W2054119723 @default.
• W2804373208 cites W2064407018 @default.
• W2804373208 cites W2073374742 @default.
• W2804373208 cites W2086942972 @default.
• W2804373208 cites W2090231128 @default.
• W2804373208 cites W2091301513 @default.
• W2804373208 cites W2104299102 @default.
• W2804373208 cites W2105962383 @default.
• W2804373208 cites W2111099202 @default.
• W2804373208 cites W2115012618 @default.
• W2804373208 cites W2125639599 @default.
• W2804373208 cites W2126127706 @default.
• W2804373208 cites W2130869061 @default.
• W2804373208 cites W2133591735 @default.
• W2804373208 cites W2135545256 @default.
• W2804373208 cites W2156465863 @default.
• W2804373208 cites W2160428712 @default.
• W2804373208 cites W2161453510 @default.
• W2804373208 cites W2509832926 @default.
• W2804373208 cites W2588614813 @default.
• W2804373208 cites W2596179513 @default.
• W2804373208 cites W2609543937 @default.
• W2804373208 cites W2616345961 @default.
• W2804373208 cites W2738197143 @default.
• W2804373208 cites W2746224452 @default.
• W2804373208 cites W4249898731 @default.
• W2804373208 doi "https://doi.org/10.1016/j.jacl.2018.05.007" @default.
• W2804373208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30318065" @default.
• W2804373208 hasPublicationYear "2018" @default.
• W2804373208 type Work @default.
• W2804373208 sameAs 2804373208 @default.
• W2804373208 citedByCount "23" @default.
• W2804373208 countsByYear W28043732082019 @default.
• W2804373208 countsByYear W28043732082020 @default.
• W2804373208 countsByYear W28043732082021 @default.
• W2804373208 countsByYear W28043732082022 @default.
• W2804373208 countsByYear W28043732082023 @default.
• W2804373208 crossrefType "journal-article" @default.
• W2804373208 hasAuthorship W2804373208A5003714120 @default.
• W2804373208 hasAuthorship W2804373208A5009467334 @default.
• W2804373208 hasAuthorship W2804373208A5016352406 @default.
• W2804373208 hasAuthorship W2804373208A5020436935 @default.
• W2804373208 hasAuthorship W2804373208A5025538949 @default.
• W2804373208 hasAuthorship W2804373208A5028132133 @default.
• W2804373208 hasAuthorship W2804373208A5035587883 @default.
• W2804373208 hasAuthorship W2804373208A5044425699 @default.
• W2804373208 hasAuthorship W2804373208A5069071892 @default.
• W2804373208 hasAuthorship W2804373208A5090781778 @default.
• W2804373208 hasBestOaLocation W28043732081 @default.
• W2804373208 hasConcept C126322002 @default.
• W2804373208 hasConcept C142724271 @default.
• W2804373208 hasConcept C168563851 @default.
• W2804373208 hasConcept C197934379 @default.
• W2804373208 hasConcept C203092338 @default.
• W2804373208 hasConcept C204243189 @default.
• W2804373208 hasConcept C204787440 @default.
• W2804373208 hasConcept C27081682 @default.
• W2804373208 hasConcept C2778114629 @default.
• W2804373208 hasConcept C2778163477 @default.
• W2804373208 hasConcept C2778375690 @default.
• W2804373208 hasConcept C2779120738 @default.
• W2804373208 hasConcept C2780072125 @default.
• W2804373208 hasConcept C2780745583 @default.
• W2804373208 hasConcept C2780902209 @default.
• W2804373208 hasConcept C2780948078 @default.
• W2804373208 hasConcept C43554185 @default.
• W2804373208 hasConcept C71924100 @default.
• W2804373208 hasConceptScore W2804373208C126322002 @default.
• W2804373208 hasConceptScore W2804373208C142724271 @default.
• W2804373208 hasConceptScore W2804373208C168563851 @default.
• W2804373208 hasConceptScore W2804373208C197934379 @default.
• W2804373208 hasConceptScore W2804373208C203092338 @default.
• W2804373208 hasConceptScore W2804373208C204243189 @default.

• next